Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | Ovarian Cancer | Research article

Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis

Authors: Bing Li, Ge Lou, Jiahui Zhang, Ning Cao, Xi Yu

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

Ovarian cancer (OC) is a female malignant tumor with a high fatality rate. Long non-coding RNAs (lncRNAs) are deeply involved in OC progression. The aim of this study is to explore the specific mechanism of lncRNA prostate androgen-regulated transcript 1 (PART1) in OC.

Methods

Quantitative real time PCR was utilized to determine the expression levels of PART1, microRNA (miR)-503-5p and forkhead-box k1 (FOXK1) in OC tissues and/or cells. The cell viability, migration, and invasion in OC were evaluated by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-h-tetrazolium bromide assay, wound healing assay and transwell invasion assay, respectively. Flow cytometry was used to analyze the cell apoptosis. The xenograft tumor was conducted in nude mice to verify the effect of PART1 knockdown on OC in vivo. The target relationships among PART1, miR-503-5p and FOXK1 were predicted by StarBase, and verified by luciferase reporter assay. The level of FOXK1 was assessed by western blot.

Results

Increased expression of PART1 and FOXK1 was observed in OC tissues or cells, whereas miR-503-5p was downregulated. PART1 silencing or miR-503-5p overexpression repressed the cell viability, migration and invasion, and protomed apoptosis. Meanwhile, miR-503-5p was a target of PART1, and FOXK1 was a direct target gene of miR-503-5p. Both downregulation of miR-503-5p and upregulation of FOXK1 partly relieved the suppressive effects of PART1 knockdown on the oncogenicity of OC in vitro.

Conclusion

Decreased PART1 represses the cell viability, migration and invasion of OC via regulating the miR-503-5p/FOXK1 axis, which provided an underlying target for treating OC.
Appendix
Available only for authorised users
Literature
1.
Shapira I, Oswald M, Lovecchio J, Khalili H, Menzin A, Whyte J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer. 2014;110(4):976–83.CrossRef
2.
Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.CrossRef
3.
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res. 2012;10(11):1462–72.CrossRef
4.
Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian Cancer. Am J Prev Med. 2016;50(3):384–94.CrossRef
5.
Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13(4):255–61.CrossRef
6.
Gupta V, Yull F, Khabele D. Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy. Cancers (Basel). 2018;10(10):366.CrossRef
7.
Zietek A, Bogusiewicz M, Szumilo J, Rechberger T. Opportunistic salpingectomy for prevention of sporadic ovarian cancer - a jump from basic science to clinical practice? Ginekol Pol. 2016;87(6):467–72.CrossRef
8.
Chi, Wang, Yu, Yang. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.CrossRef
9.
Lai XJ, Cheng HF. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290; 2018.
10.
Haihai L, Tong Y, Yue H, Hua J, Chengyu W, Tianyi Y, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101–3p to regulate ZEB1 expression. Mol Cancer. 2018;17(1):119.
11.
Wang X, Yang B, She Y, Ye Y. The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 2018;119(9):7790–9.
12.
Zhu D, Yu Y, Wang W, Wu K, Zhao S. Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway. Cancer Med. 2019;8(5):6064–81.
13.
Zhou T, Wu L, Ma N, Tang F, Chen S. LncRNA PART1 regulates colorectal cancer via targeting miR-150-5p/miR-520h/CTNNB1 and activating Wnt/β-catenin pathway. Int J Biochem Cell Biol. 2019;118:105637.CrossRef
14.
Sun M, Geng D, Li S, Chen Z, Zhao W. LncRNA PART1 modulates toll-like receptor pathway to influence cell proliferation and apoptosis in prostate cancer cells. Biol Chem. 2017;399(4):387–95.
15.
Zhao Q, Fan C. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs. BMC Med Genet. 2019;20(1):103.CrossRef
16.
Fan L-P, Chen Y-H, Yuan H-N, Xiao X-S. Lv: MiR-15a-3p suppresses the growth and metastasis of ovarian cancer cell by targeting Twist1. Eur Rev Med Pharmacol Sci. 2019;23(5):1934–46.
17.
Xiang G, Cheng Y. MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2. Reprod Biol. 2018;18(3):218–24.
18.
Hou X-S, Han C-Q, Zhang. MiR-1182 inhibited metastasis and proliferation of ovarian cancer by targeting hTERT. Eur Rev Med Pharmacol Sci. 2018;22(6):1622–8.PubMed
19.
Wu D, Lu P, Mi X, Miao J. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Arch Gynecol Obstet. 2018;297(2):699–707.CrossRef
20.
Li T, Li Y, Gan Y, Tian R, Wu Q, Shu G, et al. Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23. Cell Cycle (Georgetown, Tex). 2019;18(14):1601–18.CrossRef
21.
Sun Q, Li Q, Xie F. LncRNA-MALAT1 regulates proliferation and apoptosis of ovarian cancer cells by targeting miR-503-5p. OncoTargets Ther. 2019;12:6297–307.CrossRef
22.
Zhao X, Hong Y, Cheng Q, Guo L. LncRNA PART1 exerts tumor-suppressive functions in tongue squamous cell carcinoma via miR-503-5p. OncoTargets Ther. 2020;13:9977–89.CrossRef
23.
Yang H, Zhang X, Zhu L, Yang Y, Yin X. YY1-induced lncRNA PART1 enhanced resistance of ovarian Cancer cells to Cisplatin by regulating miR-512-3p/CHRAC1 Axis. DNA Cell Biol. 2021;40(6):821–32.CrossRef
24.
Wang Y, Liu G, Sun S, Qin J. miR-1294 alleviates epithelial–mesenchymal transition by repressing FOXK1 in gastric cancer. Genes Genomics. 2020;42(2):217–24.CrossRef
25.
Zhiqiang, Wen Z, Mao J, Xu Z, Fan M. miR-186-5p functions as a tumor suppressor in human osteosarcoma by targeting FOXK1. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2019;52(3):553–64.
26.
Yang M, Sun S, Guo Y, Qin J, Liu G. Long non-coding RNA MCM3AP-AS1 promotes growth and migration through modulating FOXK1 by sponging miR-138-5p in pancreatic cancer. Mol Med. 2019;25(1):55.
27.
Lu SR, Li Q, Lu JL, Liu C, Xu X, Li JZ. Long non-coding RNA LINC01503 promotes colorectal cancer cell proliferation and invasion by regulating miR-4492/FOXK1 signaling. Exp Ther Med. 2018;16(6):4879–85.
28.
Sun H, Wang H, Wang X, Aoki Y, Wang X. Aurora-a/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics. 2020;10(15):6928–45.CrossRef
29.
Li L, Gong M, Zhao Y, Zhao X, Li Q. FOXK1 facilitates cell proliferation through regulating the expression of p21, and promotes metastasis in ovarian cancer. Oncotarget. 2017;8(41):70441–51.CrossRef
30.
Kannan K, Coarfa C, Rajapakshe K, Hawkins SM, Matzuk MM, Milosavljevic A, et al. CDKN2D-WDFY2 Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma. PLoS Genet. 2014;10(3):e1004216.CrossRef
31.
Fan Q, Cheng Y, Chang HM, Deguchi M, Leung PCK. Sphingosine-1-phosphate promotes ovarian cancer cell proliferation by disrupting Hippo signaling. Oncotarget. 2017;8(16):27166.CrossRef
32.
Kuang D, Zhang X, Hua S, Dong W, Li Z. Long non-coding RNA TUG1 regulates ovarian cancer proliferation and metastasis via affecting epithelial-mesenchymal transition. Exp Mol Pathol. 2016;101(2):267–73.CrossRef
33.
Jin Y, Feng SJ, Qiu S, Shao N, Zheng JH. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med Pharmacol. 2017;21(14):3176–84.
34.
Lin X, Yang F, Qi X, Li Q, Wang D, Yi T, et al. LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145. Mol Carcinog. 2019;58(12):2286–96.CrossRef
35.
Pu J, Tan C, Shao Z, Wu X, Zhang Y, Xu Z, et al. Long noncoding RNA PART1 promotes hepatocellular carcinoma progression via targeting miR-590-3p/HMGB2 Axis. Onco Targets Ther. 2020;13:9203–11.CrossRef
36.
Lou T, Ke K, Zhang L, Miao C, Liu Y. LncRNA PART1 facilitates the malignant progression of colorectal cancer via miR-150-5p/LRG1 axis. J Cell Biochem. 2020;121(10):4271–81.CrossRef
37.
Li X, Han X, Yang J, Sun J, Wei P. miR-503-5p inhibits the proliferation of T24 and EJ bladder cancer cells by interfering with the Rb/E2F signaling pathway. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33(10):1360–4.PubMed
38.
Wei L, Sun C, Zhang Y, Han N, Sun S. miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-A. Gene Ther. 2020. Online ahead of print.
39.
Ran W, Zeng YH, Ma XJ, Liao P, Liu XL. The effect of miR-503-5p on the proliferation, invasion, migration and epithelial Interstitium of cervical Cancer HeLa cells via targeting E2 F3. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51(2):178–84.PubMed
40.
Wang AH, Jin CH, Cui GY, Li HY, Wang Y, Yu JJ, et al. MIR210HG promotes cell proliferation and invasion by regulating miR-503-5p/TRAF4 axis in cervical cancer. Aging (Albany NY). 2020;12(4):3205–17.CrossRef
41.
Lin L, Xin B, Jiang T, Wang XL, Yang H, Shi TM. Long non-coding RNA LINC00460 promotes proliferation and inhibits apoptosis of cervical cancer cells by targeting microRNA-503-5p. Mol Cell Biochem. 2020;475(1–2):1–13.CrossRef
Metadata
Title
Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis
Authors
Bing Li
Ge Lou
Jiahui Zhang
Ning Cao
Xi Yu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-09005-x

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue

Research

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Research

Mediators of screening uptake in a colorectal cancer screening intervention among Hispanics

Research article

Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations

Research

The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis

Research

Associations of IFT20 and GM130 protein expressions with clinicopathological features and survival of patients with lung adenocarcinoma

Research

A novel tool for predicting the risk of central lymph node metastasis in patients with papillary thyroid microcarcinoma: a retrospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits